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In vivo TCR signaling in CD4+ T cells
imprints a cell-intrinsic, transient
low-motility pattern independent of
chemokine receptor expression
levels, or microtubular network,
integrin, and protein kinase C activity
Markus Ackerknecht1, Mark A. Hauser 2, Daniel F. Legler 2 and Jens V. Stein1*
1 Theodor Kocher Institute, University of Bern, Bern, Switzerland, 2 Biotechnology Institute Thurgau (BITg), University of
Konstanz, Kreuzlingen, Switzerland
Intravital imaging has revealed that T cells change their migratory behavior during phys-
iological activation inside lymphoid tissue. Yet, it remains less well investigated how the
intrinsic migratory capacity of activated T cells is regulated by chemokine receptor levels
or other regulatory elements. Here, we used an adjuvant-driven inflammation model to
examine howmotility patterns corresponded with CCR7, CXCR4, and CXCR5 expression
levels on ovalbumin-specific DO11.10 CD4+ T cells in draining lymph nodes. We found
that while CCR7 and CXCR4 surface levels remained essentially unaltered during the first
48–72 h after activation of CD4+ T cells, their in vitro chemokinetic and directed migratory
capacity to the respective ligands, CCL19, CCL21, and CXCL12, was substantially
reduced during this time window. Activated T cells recovered from this temporary
decrease in motility on day 6 post immunization, coinciding with increasedmigration to the
CXCR5 ligand CXCL13. The transiently impaired CD4+ T cell motility pattern correlated
with increased LFA-1 expression and augmented phosphorylation of the microtubule
regulator Stathmin on day 3 post immunization, yet neither microtubule destabilization nor
integrin blocking could reverse TCR-imprinted unresponsiveness. Furthermore, protein
kinase C (PKC) inhibition did not restore chemotactic activity, ruling out PKC-mediated
receptor desensitization as mechanism for reduced migration in activated T cells. Thus,
we identify a cell-intrinsic, chemokine receptor level-uncoupled decrease in motility in
CD4+ T cells shortly after activation, coinciding with clonal expansion. The transiently
reduced ability to react to chemokinetic and chemotactic stimuli may contribute to the
sequestering of activated CD4+ T cells in reactive peripheral lymph nodes, allowing for
integration of costimulatory signals required for full activation.
Keywords: CCR7, CD4+ T cell migration, lymph node, T cell activation, stathmin, PKC
Introduction
Naive lymphocytes continuously home via high endothelial venules (HEVs) to secondary lymphoid
organs including peripheral lymph nodes (PLNs) in search of cognate Ag (1–3). In recent years,
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live two-photon microscopy (2PM) imaging has uncovered that
in non-reactive PLNs, naïve T cells perform random guided
walk on stromal cells of the T cell area with an average speed
of 10–15µm/min (4–9). Upon encounter with cognate pep-
tide–MHC (pMHC)-bearing DCs, T cell speeds decrease in a
manner dictated by TCR affinity and the amount of pMHC com-
plexes expressed on the surface of mature DCs. Subsequently, T
cells interact continuously with one or few adjacent DCs pre-
senting cognate pMHC, presumably through a fully matured
immunological synapse (IS). Approximately 1 day later, T cells
detach fromDCs and regain a motile behavior, albeit with a lower
speed than observed for naïve T cells (8–10µm/min), coincid-
ing with commitment to proliferation and the start of cytokine
production (4–9). Of note, in the days following primary DC
imprinting, CD4+ T cells remain capable to integrate secondary
signals derived from late-arriving DC immigrants (10). This is in
line with the observation that long-dwell times in lymphoid tissue
presenting cognate pMHC complexes is required for full CD4+ T
cell activation (11).
While the early pattern of T cell–DC interactions has been
well described, such as in case of the ovalbumin (OVA)-specific
DO11.10 CD4+ T cells (4, 6, 8), less is known about the regulation
of T cell motility during the expansion phase, i.e., on days 2–6 post
immunization (p.i.). In this context, chemokines have emerged
as central players governing T cell motility patterns within lym-
phoid tissue. The CCL19/CCL21 receptor, CCR7, which is highly
expressed on naïve and central memory CD4+ T cells, guides
T cell into PLNs by activating integrins on blood-borne T cells
to bind to ICAM-1 and -2 on the HEVs (12, 13). Furthermore,
CCR7 ligands contribute to T cell positioning and basal scanning
speed inside the T cell area (14). Upon activation and prolifer-
ation, CCR7 levels become gradually decreased, which together
with CD69 expression regulates sphingosine-1-phosphate recep-
tor 1 (S1P1)-mediated T cell exit from lymphoid tissue (15, 16).
Subsets of activated CD4+ T cells increase CXCR5 expression
to provide B cell help, while others increase P- and E-selectin
ligand expression prior to leaving lymphoid tissue to accumulate
at sites of inflammation (17–19). In addition, blood-borne naïve
T cells also express CXCR4, which participates in lymphocyte
adhesion in HEV (20), but does apparently not contribute to
parenchymal T cell migration (21, 22). Despite these insights,
it remains currently unknown how chemokine receptor levels
correspond to the motility patterns observed during physiological
T cell activation in 2PM experiments. Thus, decreased CD4+ T
cell motility after DC activation may be a direct consequence of
activation-induced lower expression of CCR7 or other chemokine
receptors (16). Alternatively, or in addition, decreased CD4+ T
cell motility may result from increased adhesiveness to stromal or
hematopoietic cells via increased LFA-1 expression (23), and/or
formation of late intercellular contacts with newly incoming DCs
(15). Of note, TCR signaling may also alter intracellular signaling
networks that cell-intrinsically modulate T cell motility (24). In
this context, a recent report found reduced levels of phosphory-
lated ezrin/radixin/moesin (pERM) and increased levels of phos-
phorylated stathmin (pStathmin) after in vitro CD3-stimulated
activation of human T cells (25). While lower ERM phosphoryla-
tion impairs uropod formation, increased pStathmin levels cause
microtubule network stabilization that correlated with decreased
in vitro chemotaxis (25). Whether such a mechanism correlates
with migration parameters during physiological T cell activation
has not been addressed to date. Interestingly, chemokine receptors
also undergo regulatory processes by receptor desensitization that
is initiated by the phosphorylation of the receptor upon ligand
binding. In the case of CCR7, receptor phosphorylation of serine
and threonine residues within the cytoplasmic loops and the C-
terminus has been described to depend on G protein coupled
receptor kinases (GRKs) (26) or second-messenger-dependent
protein kinases including protein kinase C (PKC) (27). Notably,
TCR signaling leads to activation of PKC isoforms that have been
described to phosphorylate chemokine receptors in the absence
of chemokine ligands to desensitize chemokine receptors in an
heterologous manner (28).
In the present study, we examined motility patterns of in vivo-
activated adoptively transferred CD4+ T cells using a reductionist
in vitro chemotaxis system that allowed to precisely compare
chemokine receptor surface levels with migratory capacity while
employing non-TCR transgenic endogenous CD4+ T cells pop-
ulation as internal control for the inflammatory milieu. Our
data uncover a cell-intrinsic loss of motility in CD4+ T cells
shortly after activation coinciding with clonal expansion that is
independent of chemokine receptor levels, microtubular network
integrity, or PKC signaling. The reduced ability of CD4+ T cells
to react to chemokinetic and chemotactic stimuli may contribute
to control their lymphoid tissue dwell time, allowing subsets
of activated cells integrating additional signals required for full
activation before egress.
Materials and Methods
Reagents
Biotinylated or PE-, PerCP,- or APC-conjugated mAbs against
mouse CXCR4 (clone 2B11), CXCR5 (2G8), CD44 (IM7), LFA-
1 (2D7), CD25 (PC61), IL-2 (JES6-5H4), IFN-γ (XMG1.2), and
PE-or APC-conjugated streptavidin were from BD Biosciences
(Allschwil, CH), and FITC-conjugated anti-CD4 mAb (RM4–5)
was from Biolegend (San Diego, CA, USA). CCR7 was detected
using a CCL19–Ig fusion protein as described (29) (kindly pro-
vided by U. H. von Andrian, Harvard Medical School), followed
by biotinylated or PE-conjugated goat anti-human Fc Abs (Beck-
man Coulter, Fullerton, CA, USA). The specificity of CCL19–Ig
binding to CCR7 on T cells was confirmed comparing labeling
of wild type and CCR7 /  T cells (not shown) (29–31). Alterna-
tively, we labeled cells with biotinylated anti-CCR7 mAb (4B12)
from eBioscience, using isotype-matched biotinylated anti-rat
IgG2a (R35–95) as control. Unconjugated mAb for phosphory-
lated ezrin/radixin/meoosin (pERM) and pAb for phosphorylated
Stathmin (pStathmin) were purchased from Cell Signaling Tech-
nology (#3149, Danvers, MA, USA) and Bioss (bs-9765, Woburn,
MA, USA), respectively. For detection of the DO11.10-TCR spe-
cific for OVA 323–339, we employed FITC-, PE, or TRI-COLOR-
conjugated mAb KJ1–26 (Caltag, Burlingame, CA, USA). Block-
ing mAbs against αL- (FD441.8) and α4-integrin (PS/2) were
from nanotools (Freiburg, Germany). We obtained 5-(and-6)-
carboxyfluorescein diacetate, succinimidyl ester [5(6)-CFDA-SE]
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from Molecular Probes (Eugene, OR, USA). Murine CCL19,
CCL21, and CXCL12 were from Peprotech (London, UK), and
murine CXCL13 was from R&D systems (Minneapolis, MN,
USA).OVA, saponin, and nocodazole were purchased fromSigma
(St. Louis, MO, USA). OVA peptide 323–339 (OVA323–339) was
produced by Fernando Roncal at the National Center for Biotech-
nology (Madrid, Spain).
Mice, Lymphocyte Preparation, and Adoptive
Transfer
All mice used in this study were on a BALB/c background and
housed and bred under specific pathogen-free conditions. Total
lymphocytes were isolated from spleens and lymph nodes of 6- to
10-week-old DO11.10-TCR transgenic mice (Jackson Laborato-
ries, Bar Harbor, ME, USA). After erythrocyte lysis, CD4+ T cells
were isolated using negative magnetic bead separation (Dynal,
Oslo, Norway, or StemCell Technologies, Grenoble, France).
Purity of sorted CD4+ T cells was routinely>95% and contained
70–80% KJ1–26+ cells. Approximately, 2.5 106 DO11.10 CD4+
T cells were injected i.v. into age- and sex-matched BALB/c recip-
ient mice. In some experiments, sorted CD4+ T cells were labeled
prior to adoptive transfer with 2µM 5(6)-CFDA-SE for 45min,
at 37°C. One day after adoptive transfer, recipient mice received
s.c. injections of a 1:1 emulsion of complete Freund’s adjuvant
(CFA) and 20mg/ml OVA (in PBS) or, alternatively, 3mg/ml
OVA323–339 in five points closed to inguinal, axillary, brachial, and
cervical PLNs (50µl/site). Animal work has been approved by the
Cantonal Committee for Animal Experimentation and conducted
according to federal and cantonal guidelines.
Flow Cytometry
At indicated times, single cell suspensions were prepared from
draining PLNs (brachial, cervical, axillary, inguinal) of recipient
mice as described (7), and incubated for 1 h at 37°C in complete
medium (CM-R; RPMI/10% FCS/standard supplements). After
blocking Fc receptors with PBS containing 5% rat and mouse
serum (30min, 4°C), cells were washed in PBS and mAbs were
added. Flow cytometric analysis was carried out on an LSR II or
FACScalibur and analyzed with CellQuest Pro (BD Biosciences)
or FlowJo (FlowJo, Ashland, OR, USA) software. For pERM and
pStathmin staining, single cell suspensions were fixed in 4%
PFA/PBS immediately after harvest. Cell surface marker staining
was performed as described above prior to cell permeabilization
with 0.1% saponin/PBS (15min on ice). After Fc receptor block-
ing, primary and secondary antibodies were incubated for 1 h
and 30min, respectively (4°C). Lymphocyte gating was performed
according to FSC/SSC properties without exclusion of doublets
(Figure S1 in Supplementary Material).
Chemotaxis Assays
Unsorted single cell suspensions from draining PLNs were resus-
pended in CM-R (5 106 cells/ml) and chemotaxis assays were
performed using 5 105 cells/well according to the manufac-
turer’s instructions (Transwell 5µmpore size, CoStar, Cambridge,
MA, USA). In some experiments, cells were pretreated with indi-
cated concentrations of Nocodazole for 10min and throughout
the chemotaxis assay. Blocking mAbs to αL- and α4-integrins
were applied at 1µg/106 cells for 20min prior to chemotaxis
assays. Adhesion and homing experiments have shown complete
blocking of these integrins at indicated concentrations (13). After
2 h at 37°C, 5% CO2, input, and migrated cells were labeled with
mAbs against CD4 and DO11.10. From the number of migrated
cells and the percentage of CD4+ and KJ1–26+ cells in top and
bottom chamber, we calculated the percentage of migrated cells
for each condition. In each experiment, we also determined spon-
taneous migration in the absence of chemokine, which was used
to subtract chemokinesis from chemokine-induced migration. To
determine cell death, we labeled input lymphocyte populations
with propidium iodide at the end of the experiment. For chemo-
taxis of in vitro activated T cells, we treated lymphocytes for
2 days with anti-CD3 and anti-CD28 mAbs (1µg/ml), washed,
and mixed them with freshly isolated lymphocytes in a 1:20
ratio to mimic lymphocyte suspensions isolated from inflamed
PLNs. For chemotaxis of activated T cells in the presence of PKC
inhibitors, we treated splenocytes for 2 days with anti-CD3 and
anti-CD28 mAbs (1µg/ml), washed them, and treated cells with
1 or 10µM of the pan-PKC inhibitor BIM (Bisindolylmaleimide
X hydrochloride, Sigma-Aldrich, B3931, in DMSO) or DMSO
for 2 h at 37°C before chemotaxis toward 25 or 50 nM CCL21
in the presence of the inhibitors or vehicle (1 105 cells/well).
The remaining activated splenocytes were used for western blot
analysis as described below.
Homing Assays and 3-DIF
CD4+ T cells were purified from draining lymph nodes on day
3 after OVA/CFA immunization by negative selection accord-
ing to manufacturer’s instructions (StemCell Technologies, Van-
couver, CA, USA) and sorted for KJ1–26+ and KJ1–26  cells
using a FACS Aria III (BD Biosciences). 3.5 to 4 105 KJ1–26+
and 2.4 to 3 106 KJ1–26  CD4+ T cells were fluorescently
labeled and injected into age and sex-matched Balb/c recipi-
ents. After 3–5 h, PLNs were harvested and processed for 3-
D immunofluorescence (3-DIF) as described (15). In brief,
PLNs were fixed o.n. in 1% PFA/PBS, carefully cleaned from
surrounding fat tissue, embedded in 1.3% low-melting point
agarose (Invitrogen), dehydrated o.n. in 100%MeOH, and cleared
o.n. in benzyl alcohole:benzyl benzoate (BABB, 1:2). Image
stacks of 400µm 400µm 300–400µm were imaged using a
two-photon microscope (Trimscope, LaVision Biotech, Bielefeld,
Germany). Cells were localized and quantified using Volocity
(Improvision, Perkin Elmer, Cambridge, UK).
Immunofluorescence Staining
Naive CD4+ T cells from DO11.10 mice were treated for
10min with indicated nocodazole concentrations, transferred to
poly--lysine-coated cover slips for 20min before fixation with
4% PFA/PBS (20min at RT), and permeabilized using cytop-
erm/cytofix solution (20min, RT; BD Biosciences). As primary
antibody, we used rabbit-anti α/β-tubulin (1:50 dilution, 2 h at
RT; Cell Signaling Technology #2148), followed by Alexa488-
conjugated goat-anti-rabbit-IgG (1 h at RT; Invitrogen #A-11008).
Samples were analyzed using a Nikon Eclipse E600 microscope
equipped with a 60 oil objective (NA 1.4) and NIS elements
software (Nikon).
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Western Blot Analysis of PKC Isoforms
Freshly isolated or in vitro-activated splenocytes (2 106
cells/sample) were lysed in NP40 lysis buffer supplemented
with phosphatase inhibitor cocktail (PhosStop, Roche), Protease
inhibitor cocktail (complete Mini, Roche), 1mM Na3VO4, and
1mM NaF. After determining the protein concentration, we
loaded 30µg protein/lane. All PKC mAbs used were from Cell
Signaling Technology (# 2051, 2052, 2054, 9371, 9374, 9375, 9376,
9377, 9378), and anti-beta actin was from Abcam (# ab8227).
Statistical Analysis and Graphs
Box and whiskers graphs were compiled using Prism (Graphpad),
with the box showing the 25th to 75th percentiles and thewhiskers
reaching to the lowest and highest values. The line in the box
shows the median. Statistical tests were performed using ANOVA
or Student’s t-test as indicated in the figures (Prism, Graphpad).
Significance was set at p< 0.05.
Results
Kinetic Analysis of Expansion and Activation
Marker Expression of OVA-Specific DO11.10
CD4+ T Cells During Inflammation
Previous 2PM studies of reactive PLNs have shown that DO11.10
CD4+ T cells decreased their migration speed after activation by
DCs, often moving slowly in spatially confined “swarms” (4, 6).
To investigate the relationship between in vivo activation pheno-
type and migratory capacity to defined chemokines, we set up
an inflammation model to follow the expansion of Ag-specific
CD4+ T cells and to compare their behavior with an endoge-
nous CD4+ T cell control population. To mimic experimental
conditions used in previous 2PM studies, we transferred 2 to
3 106 DO11.10 CD4+ T cells into syngeneic Balb/c recipient
mice, which were s.c. immunized 1 day later with OVA emulsified
in CFA. On the day of OVA/CFA administration, some mice
did not receive OVA/CFA (=day 0), while others were sacrificed
1–9 days post immunization (p.i.) to isolate reactive PLNs for flow
cytometry and chemotaxis assays (Figure 1A). While DO11.10
CD4+ T cell expansion is a well-known consequence of OVA
immunization, we set out to determine the precise kinetics of
this process, which may vary between laboratories. OVA/CFA
immunization caused an increase in total PLN cell numbers, rising
from 23.8 5.1 106 (mean SD) on day 0 to 72.1 14.4 106
cells on day 6 p.i. before slowly decreasing to 62.1 12.7 106 on
day 9 p.i. (Figure 1B). Similarly, the endogenous KJ1–26  CD4+
T cell population in reactive PLNs doubled from 12.9 2.3 106
cells on day 0 to 25.1 5.0 106 cells on day 6 p.i., and remained
stable at 24.0 5.1 106 cells on day 9 p.i. (Figure 1C). In con-
trast to the sustained increase of endogenous CD4+ T cells, Ag-
specific DO11.10 CD4+ T cells showed amuchmore pronounced
expansion and contraction. The number ofDO11.10CD4+ T cells
increased from 0.17 0.0 106 cells on day 0 to 3.2 0.9 106
cells on day 3 p.i. before sharply falling to 0.9 0.3 106 cells
on day 9 p.i. (Figure 1D) and becoming barely detectable on day
13 p.i. (not shown). On days 4 and 5 p.i., the total numbers of
PLN cells, endogenous CD4+ T cells, and DO11.10 CD4+ T cells
remained on the levels of days 3–6 (not shown) indicating that
after 3 days p.i., near-maximal Ag-specific CD4+ T cell expansion
is reached. Accordingly, on day 3 p.i., we found that adoptively
transferred KJ1–26+ but not KJ1–26  CD4+ T cells had under-
gone extensive cell divisions (Figure 1E). In contrast to non-TCR
transgenic KJ1–26  DO11.10 CD4+ T cells, KJ1–26+ DO11.10
CD4+ T cells expressed proinflammatory cytokines (IL-2, IFNγ)
and showed increased CD25, CD44, and LFA-1 surface levels
corresponding to bona fide hallmarks of activation (Figure 1F).
Dynamic Regulation of CCR7, CXCR4, and
CXCR5 Levels on Activated DO11.10 CD4+
T Cells
Building on the kinetics established for the OVA/CFA immuniza-
tion model, we performed a side-by-side flow cytometric analysis
of chemokine receptors, CCR7, CXCR4, and CXCR5, expressed
on endogenous and KJ1–26+ DO11.10 CD4+ T cells. Using a
CCL19–Ig fusion protein to label CCR7 (29), we found CCR7
surface expression levels on DO11.10 CD4+ T cells to remain
similar or even slightly increased compared to endogenous CD4+
T cells on day 1 and 2 p.i. before gradually decreasing to 40% of
levels of non-activated CD4+ T cells on day 9 p.i. (Figures 2A,B;
Figures S1A,B in Supplementary Material). Similar results were
obtained when we used an anti-CCR7 mAb (not shown). By
contrast, CXCR4 MFI levels remained stable on endogenous and
DO11.10 CD4+ cells (Figures 2C,D). Similarly, the percentages
of CXCR4+ KJ1–26+ versus endogenous CD4+ T cells was com-
parable on day 3 (24.9 4.5 versus 25.5 1.9%, respectively) and
day 6 p.i. (25.9 14.0 versus 22.1 3.6%, respectively). As pre-
dicted from previous studies (18), CXCR5 expression started to
increase on day 3 p.i. (not shown), with an inverse correlation
between CCR7 and CXCR5 levels on days 5 and 6 p.i. Thus, while
25.8 1.4% of all DO11.10 CD4+ T cells expressed CXCR5 on
days 5 and 6 p.i., this percentage increased to 48.9 2.1% for the
CCR7low subpopulation, whereas only 14.1 2.1% of CCR7high
DO11.10 CD4+ T cells expressed CXCR5 (Figure 2E). In addi-
tion, the relative CXCR5 MFI of CCR7low DO11.10 CD4+ T
cells was increased by 62% over the one of CCR7high cells when
normalized to isotype control (Figure 2F). At this time point,
the percentage of endogenous CXCR5+ CD4+ T cells remained
low at 8.1 0.5%, presumably owing to strong competition by
high numbers of adoptively transferred Ag-specific CD4+ T cells.
In sum, our data uncover a gradual decrease in CCR7 levels on
DO11.10 CD4+ T cells starting on day 3 p.i., which coincided
with massive expansion and CXCR5 upregulation on a subset of
transferred cells.
In Vitro Migration Assays Identify an
Activation-Induced Transient Decrease of
Intrinsic DO11.10 CD4+ T Cell Motility Uncoupled
of Chemokine Receptor Surface Levels
While parenchymal T cell migration follows a random guided
motility pattern, chemokine receptors participate in their motility.
We therefore performed Transwell chemotaxis assays as surrogate
tool to examine the functionality of CCR7, CXCR4, and CXCR5
on activated CD4+ T cells during directed in vitro migration,
while correlating these data to receptor surface levels. When we
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FIGURE 1 | Kinetic of DO11.10 CD4+ T cell expansion and activation
after OVA/CFA immunization. (A) Outline of experiment. DO11.10 CD4+
T cells were adoptively transferred 1 day before s.c. OVA/CFA immunization.
Draining PLNs were analyzed by flow cytometry and chemotaxis. (B) Total
pooled PLN lymphocyte numbers during OVA/CFA immunization. (C) Total
CD4+ T cell numbers in pooled PLNs during OVA/CFA immunization.
(D) Total KJ1–26+ CD4+ T cell numbers in pooled PLNs during OVA/CFA
immunization. (E) Representative flow cytometry plots of adoptively
transferred CFSE-labeled KJ1–26  and KJ1–26+ cells on day 0 (top panel;
R1) and on day 3 post OVA peptide/CFA (middle panel) or OVA/CFA
(bottom panel) immunization (R2 and R3, respectively). (F) Flow cytometry
analysis of activation markers of KJ1–26  and KJ1–26+ cells in gates R2
and R3 as shown in (E) after priming with peptide. Similar results were
obtained with OVA immunization. Numbers indicate percentages in gated
populations. Data in (B–D) are pooled from 6 independent experiments
combining 4–13 mice/time point and are shown as box and whiskers
graphs as described in the section “Materials and Methods.” Flow
cytometry plots in (E,F) are representative of two independent experiments.
Statistical analysis was performed using ANOVA test against “Day 0” values
followed by Dunnett’s multiple comparison test. **p<0.01; ***p<0.001.
analyzed spontaneous motility of isolated endogenous and adop-
tively transferred CD4+ T cells, we observed on days 1 and 2
p.i. a transient decrease in DO11.10 CD4+ T cells chemokine-
independent motility. By contrast, endogenous CD4+ T cells
showed sustained chemokinetic motility peaking on day 2 and 3
p.i. (Figure 3A; Figure S1C in Supplementary Material), poten-
tially induced by exposure to chemokinetic factors such as throm-
boxane A2 (32, 33). We next focused on chemokine-induced
motility after subtracting the corresponding values of sponta-
neous migration observed in Figure 3A. We did not detect sig-
nificant differences in the capacity of endogenous CD4+ T cells
to migrate to CCL19, CCL21, CXCL12, and CXCL13 irrespec-
tive of the day p.i. analyzed, indicating that the inflammatory
milieu had no effect on chemokine-induced migration of these
cells (Figures 3B–F). By contrast, we observed a reduction of
more than 50% in chemokine-induced migration of DO11.10
CD4+ T cells to 100 nM CCL19 and 50 nM CCL21 on days 2
and 3 p.i. (Figures 3B,C). DO11.10 CD4+ T cells showed a non-
significant tendency to lower migration to 100 nM CCL21 on day
3 p.i. (Figure 3D), suggesting that decreased motility could be
partially rescued using higher chemoattractant concentrations. It
is noticeable that DO11.10 CD4+ T cell migration to CCL19 and
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FIGURE 2 | Chemokine receptor regulation on DO11.10 CD4+ T cells
after OVA/CFA immunization. (A) Top panel. Representative flow
cytometry plots showing expansion and contraction of adoptively
transferred KJ1–26+ DO11.10 CD4+ T cells in OVA/CFA-draining PLNs.
Bottom panel. Corresponding flow cytometry plots of CCR7 expression on
endogenous CD4+ (black) and DO11.10 CD4+ T cells (red). Dashed lines
show secondary mAb only. (B) Ratio of CCR7 MFI on KJ1–26+ CD4+
versus endogenous CD4+ T cells after OVA/CFA immunization. (C) Flow
cytometry plots of CXCR4 expression on KJ1–26+ CD4+ and endogenous
CD4+ T cells after OVA/CFA immunization. The isotype control is shown in
gray. (D) Ratio of CXCR4 MFI on KJ1–26+ CD4+ versus endogenous
CD4+ T cells after OVA/CFA immunization. (E) Left panel. Gating strategy
for CCR7low and CCR7high CD4+ KJ1–26+ T cells on day 5 post OVA/CFA
immunization. CCR7 levels on endogenous CD4+ KJ1–26  T cells are
depicted in green. Right panel. CXCR5 expression levels on CCR7low (black)
and CCR7high (red) CD4+ KJ1–26+ T cells. The isotype control is shown in
blue. (F) Ratio of CXCR5 MFI on CCR7low and CCR7high KJ1–26+ CD4+ T
cells on days 5/6 after OVA/CFA immunization, normalized to isotype
control. Data are pooled from 2–5 independent experiments combining
4–10 mice/time point. Data in (B,D,F) were analyzed using ANOVA and
Dunnett’s (B,D) or Tukey’s (F) multiple comparison test and are shown as
box and whiskers graphs. **p<0.01; ***p<0.001.
CCL21 on days 6 and 9 p.i. returned to the levels of endogenous
CD4+ T cells despite decreased CCR7 surface expression levels
at these time points (Figure 2B). Similar to observations made
with CCR7 ligands, DO11.10 CD4+ T cells migration to CXCL12
was virtually abolished on day 3 p.i. (Figure 3E). On the other
hand, CXCL13-induced motility correlated well with increased
CXCR5 expression levels on these cells during the course of the
immune response (Figure 3F). Migration patterns were compara-
ble when we quantified chemotaxis without subtraction of back-
ground migration (Figure S2 in Supplementary Material). Finally,
we examined in vitro chemotaxis of sorted KJ1–26+ and KJ1–26 
CD4+ T cells on day 3 p.i., confirming a cell-intrinsic reduction in
spontaneous and CCL21-induced migration of recently activated
T cells in purified populations (Figure S3E in Supplementary
Material). Less than 2.5% of endogenous or activated T cells
were propidium iodide-positive after in vitro incubation for 2 h,
excluding cell death as reason for decreased numbers of migrated
T cells (Figure S1D in Supplementary Material). Taken together,
our chemokinetic and chemotacticmigration experiments uncov-
ered a transient TCR-induced decrease of DO11.10 CD4+ T cell
motility on days 2 and 3 p.i., whichwas at least partially uncoupled
from CCR7 and CXCR4 expression levels.
Reduced In Vitro Motility of Activated DO11.10
CD4+ T Cells Correlates with Decreased In Vivo
Homing
To assesswhether lower in vitro chemotaxis of activatedT cells was
reflected in altered lymphoid tissue motility, we performed 2PM
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FIGURE 3 | In vitro migration of endogenous and DO11.10 CD4+
T cells during OVA/CFA immunization. (A) In vitro chemokinesis of
endogenous CD4+ T cells (white bars) and KJ1–26+ DO11.10 CD4+ T
cells (black bars) in the absence of chemokine after OVA/CFA immunization.
(B) Chemotaxis to 100 nM CCL19. (C) Chemotaxis to 50 nM CCL21.
(D) Chemotaxis to 100 nM CCL21. (E) Chemotaxis to 100 nM CXCL12.
(F) Chemotaxis to 250 nM CXCL13. Chemokinetic migration (A) was
subtracted in (B–F) to focus on chemokine-induced motility. Bars represent
meanSD of % input and were pooled from three to four independent
experiments combining three to eight mice per time point. Statistical
analysis was performed separately for endogenous CD4+ T cells and
KJ1–26+ DO11.10 CD4+ T cells using ANOVA test against “Day 0” values
(=control migration) followed by Dunnett’s multiple comparison test.
*p<0.05; **p<0.01; ***p<0.001.
experiments with sorted KJ1–26  and KJ1–26+ CD4+ T cells
on day 3 post OVA/CFA immunization, the earliest time point
at which Ag-specific DO11.10 T cells had sufficiently expanded
for sorting (Figure 1D). Since we still obtained too few KJ1–26+
CD4+ T cells for 2PM imaging after systemic transfer, we used
microinjection to deliver fluorescently labeled T cells directly
into surgically exposed popliteal PLNs prior to imaging. While
we readily identified transferred T cells in lymphoid tissue by
this approach, we found that their motility was severely compro-
mised irrespective of their activation status, precluding a mean-
ingful 2PM analysis (not shown). We also examined whether the
reduced responsiveness of recently activated DO11.10 CD4+ T
cells toward CCR7 ligands was reflected in short-term homing
assays, since this receptor is together with L-selectin and LFA-1
critical for T cell entry into PLNs (2). We sorted KJ1–26+ and
KJ1–26  CD4+ T cells from reactive PLNs of Balb/c mice after
their expansion on 3 days p.i., labeled these cells fluorescently and
adoptively transferred them into non-immunized sex-matched
recipient mice for 3–5 h before PLN excision (Figures S3A,B in
Supplementary Material). Owing to the low number of KJ1–26+
CD4+ T cells recovered after sorting for adoptive transfer, we
performed a high-sensitivity three-dimensional immunofluores-
cence (3-DIF) analysis of whole-mount PLNs, rather than con-
ventional flow cytometry (13). In brief, after optical clearing of
entire PLNs of recipient mice, we optically sectioned large 3-D
volumes using 2PM scanning to detect rare adoptively transferred
cells, in addition to their precise localization with regard to the
HEV network (Figure S3C in Supplementary Material). Using
this approach, we were able to identify adoptively transferred cell
populations and compare their relative frequency with one of the
input population. We found that, despite comparable expression
of the adhesion molecule L-selectin on both cell populations (not
shown) and increased LFA-1 expression on KJ1–26+ CD4+ T
cells (Figure 1F), DO11.10 CD4+ T cells were underrepresented
in PLNs as compared to their input frequency (Figure S3D in
Supplementary Material). While this may have been partially due
to lower CCR7 levels on activated DO11.10 CD4+ T cells on day
3 p.i., these data are consistent with the generally reduced in vitro
chemotactic responsiveness of recently activated CD4+ T cells to
chemokines (Figure 3).
Transient Increase in pStathmin Levels on
In Vivo-Activated DO11.10 CD4+ T Cells
Since chemokine responsiveness of recently activated DO11.10
CD4+ T cell did not match well with chemokine receptor sur-
face levels, we hypothesized that activation-induced intracellu-
lar signaling pathways resulted in lower intrinsic cell motil-
ity. In vitro TCR activation of human T cells leads to ERM
dephosphorylation and stathmin phosphorylation, which cause
decreased T cell motility owing to decreased uropod forma-
tion and increased microtubule network stability (25). When we
examined the phosphorylation status of these molecules on day
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FIGURE 4 | Dynamic regulation of pERM and pStathmin levels in
DO11.10 CD4+ T cells. (A) Representative flow cytometry plots showing
intracellular pERM levels on endogenous CD4+ versus KJ1–26+ DO11.10
CD4+ T cells on days 0, 3, and 6 post OVA/CFA immunization. The gray line
represents secondary Ab only. (B) Ratio of pERM levels on endogenous CD4+
versus KJ1–26+ DO11.10 CD4+ T cells. (C) Representative flow cytometry
plots showing intracellular pStathmin levels on endogenous CD4+ versus
KJ1–26+ DO11.10 CD4+ T cells on days 0, 3, and 6 post OVA/CFA
immunization. The gray line represents secondary Ab only. (D) Ratio of
pStathmin levels on endogenous CD4+ versus KJ1–26+ DO11.10 CD4+ T
cells. Data in (A,C) are representative of two independent experiments, while
data in (B,D) are pooled from six mice in two independent experiments and
shown as meanSD. Data were analyzed using ANOVA with Tukey’s multiple
comparison test. ***p<0.001.
0, 3, and 6 post OVA/CFA immunization, we found a minor
1.5-fold sustained increase in pERM levels in DO11.10 CD4+ T
cells as compared to endogenous CD4+ T cells (Figures 4A,B;
Figure S1E in Supplementary Material). By contrast, we observed
a transient and substantial fourfold increase in pStathmin levels in
DO11.10 CD4+ T cells on day 3 p.i., which decreased by day 6 p.i.
(Figures 4C,D). Of note, pStathmin levels remained elevated for
at least 2 h after T cell isolation (not shown), suggesting that high
pStathmin levels were maintained in the absence of continued
TCR stimulation.
Microtubule Network Destabilization, Integrin
Blocking, or PKC Inhibition Does Not Restore the
Migratory Capacity on Recently Activated T Cells
It is well established that pStathmin levels positively correlate
with microtubular network stability (34, 35). We therefore exam-
ined whether disrupting microtubule stability using nocodazole
reverses the low in vitro motility of activated CD4+ T cells.
We isolated PLNs 3 days after OVA/CFA immunization and pre-
incubated single cell suspensions with increasing concentrations
of nocodazole prior to and during chemotaxis. Using immunoflu-
orescence, we confirmed that increasing nocodazole treatment
disrupted the lymphocyte microtubule network (Figure 5A).
By contrast, nocodazole treatment at 0.1 and 1µM did not
alter chemokinetic motility and chemotaxis to CCL21 of nei-
ther endogenous nor KJ1–26+ CD4+ T cells (Figures 5B,C).
We made similar observations with both lower (0.01µM) and
increased (10µM) nocodazole concentrations (not shown). Next,
we investigated whether increased integrin adhesiveness causes
cell aggregation, thereby decreasing in vitromigration. Yet, similar
to nocodazole treatment, blocking α4 and αL integrins did not
rescue the reducedKJ1–26+ CD4+ Tcellmigration in the absence
or presence of CCL21 (Figures 5B,C).
Finally, we examined the role of a potential TCR-driven PKC-
mediated phosphorylation leading to a loss of chemokine receptor
signaling through receptor desensitization. To obtain activated
CD4+ T cells in large enough numbers for Western blot analysis,
we performed in vitro activation experiments using anti-CD3/28
mAb stimulation. Owing to lack of appropriate tools, we were
unable to directly assess CCR7 phosphorylation levels in acti-
vated T cells (not shown). Yet, we confirmed that in both freshly
isolated and day 2 in vitro-activated lymphocyte suspensions,
conventional, novel, and atypical PKC isoforms were expressed
and phosphorylated. In particular, activated lymphocytes showed
increased phosphorylation of PKCζ/λ and PKCµ (Figure S4 in
Supplementary Material). Furthermore, when we mixed freshly
isolated and day 2 in vitro-activated lymphocyte suspensions in a
ratio similar to in vivo-derived suspensions, we were able to reca-
pitulate decreased chemotaxis of activated T cells to 25 nMCCL21
(Figures 5D,E). Yet, preincubation of day 2 in vitro-activated
lymphocyte suspensions with the pan-PKC inhibitor BIM did
not rescue the decreased chemotactic motility (Figure 5F). Sim-
ilar results were obtained when we performed migration assays
to 50 nM CCL21 (not shown). Taken together, these functional
assays argue against a role for microtubular network stability,
integrin activity, or PKC activity during the motility shutdown
experienced by recently activated CD4+ T cells.
Discussion
TCR-driven CD4+ T cell activation imprints substantial changes
in gene transcriptional programs, which result in cell proliferation
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FIGURE 5 | Activation-induced decrease in T cell motility is maintained
in the presence of microtubule destabilization agents, integrin blocking,
and PKC inhibition. (A) Immunofluorescent analysis of microtubule networks
(green) of CD4+ T cells in the presence or absence of nocodazole. Nuclei are
labeled with DAPI (blue). Scale bar, 5µm. (B) Chemokinesis of endogenous
CD4+ versus KJ1–26+ DO11.10 CD4+ T cells on day 3 after OVA/CFA
immunization in the presence of nocodazole or integrin-blocking mAbs. (C)
Chemotaxis to 25 nM CCL21. (D) Chemokinesis of day 2 in vitro-activated
lymphocytes mixed 1:20 with non-activated lymphocytes. (E) Chemotaxis of
in vitro-activated lymphocytes. (F) Chemotaxis of day 2 in vitro-activated
lymphocytes to 25 nM CCL21 in the presence of the PKC inhibitor BIM. No
significant differences were detected. Chemokinetic migration was subtracted in
(C,E,F) to focus on chemokine-induced motility. Bars represent meanSD of
% input. Data in (B,C) are pooled from two independent experiments with five
mice total and were analyzed using an unpaired Student’s t-test. Data in (D–F)
are from one to three independent experiments with a total of four mice and
were analyzed using ANOVA and Sidak’s multiple comparison tests. *p<0.05;
**p<0.01; ***p<0.001.
and altered expression of adhesion and chemoattractant recep-
tors. How these changes influence intrinsic CD4+ T cell motility
and responsiveness to chemoattractants has not been examined
in detail to date. In this study, we show that recently activated
CD4+ T cells show a temporal unresponsiveness to spontaneous
and chemokine-induced motility in vitro and in vivo, which was
uncoupled from integrin and chemokine receptor levels, PKC
activity, or microtubular network stability. This transient low-
motility pattern was particularly noticeable under conditions of
low-chemotactic gradient strength, since increasing concentra-
tions of CCL21 were able to partially rescue this defect.
Two-photon microscopy studies have uncovered a multistep
model for T cell–DC interactions, which are characterized by a
gradual decrease in T cell motility until reaching a threshold for
complete arrest and long-term interactions with cognate pMHC-
bearing DCs. Finally, after detachment from DCs and commit-
ment to cell proliferation, CD4+ T cells resume motility, albeit at
lower speeds than the ones shown by unstimulated naïve T cells
(4, 6). Shortly after activation, T cells increase CD69 expression
and downregulate S1P1, which contributes to lymphocyte seques-
tering in lymphoid tissue (36). Our data provide evidence for
a cell-intrinsic mechanism regulating basal and chemokine-
triggered motility in proliferating CD4+ T cells, which is largely
independent of the surface expression levels of CCR7 or CXCR4
and may also contribute to lymphocyte sequestering in lymphoid
tissue. Thus, we observed reduced in vitroT cellmotility as early as
1–2 days p.i., when chemokine receptor levels were unchanged. In
contrast to CD8+ T cells, which undergo an “autopilot” program
of multiple cell divisions after a short DC-mediated stimulus
(37), CD4+ T cells require continuous signaling for full pro-
liferation (38, 39). Thus, reduced motility shortly after activa-
tion may constitute an additional mechanism to ensure sufficient
PLN dwelling time to engage in productive interactions with
late-arriving DCs or prolonged signal integration by exposure
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to inflammatory cytokines. In line with this hypothesis, acti-
vated CD4+ T cells readily engage with late-arriving DCs lead-
ing to increased activation (10). Thus, a temporal shutdown of
CD4+ T cell responsiveness to chemoattractants may ensure pro-
longed dwelling time for full signal integration. At later time
points, reduced CCR7 levels during inflammation correlate with
increased S1P1 levels, which facilitate egress of recently acti-
vated lymphocytes (16). An interesting aspect of our analysis is
the similar migration of endogenous CCR7high versus CCR7low
DO11.10 CD4+ T cells to CCL19 or CCL21 after day 6 p.i.,
although the latter population contained CXCR5high CD4+ T
follicular helper (TFH) cells residing in B cell follicles. These
data suggest that chemokine receptor levels on T cells do not
necessarily correspond with in vitro migratory capacity, similar
to what has been described in B cells (40). The recovery of
robust migration in activated CD4+ T cells starting on day 6
p.i. is in line with the recently described high motility of TFH
within germinal centers, as well as their ability to move between
follicles (41).
Two-photon microscopy studies have demonstrated that after
detachment from DCs, recently activated CD4+ T cells display a
confined swarming behavior in proximity to DC clusters (6), and
in vitro-activated T cells typically form LFA-1-dependent clusters.
We hypothesized that increased LFA-1-mediated adhesion to its
ligands ICAM-1 and -2 expressed on other hematopoietic cells
may cause these cells to migrate less efficiently in our in vitro
assays. Yet, mAb blocking did not recover the low motility of
activated CD4+ T cells. Taken together, our data show that extra-
cellular factors are unlikely to be involved in decreased DO11.10
CD4+ T cell motility.
What are the TCR-triggered intracellular signaling events caus-
ing low-intrinsic cell motility? On day 3 p.i., we observed a TCR-
driven peak in pStathmin level in proliferating CD4+ T cells,
pointing to an active microtubule network required for ongoing
cell divisions. Pharmacological disruption of the microtubular
network by nocodazole or other drugs interferes with LFA-1-
dependent in vitro motility of human T cell lines (42, 43), as
well as with CCL21-triggered LFA-1 adhesiveness of lymphocytes
under flow (44). By contrast, nocodazole had previously been
used to enhance integrin-independent migration of a CD4+ T
cell line through 3µm pores by relaxing the microtubular net-
work (45). Here, we found no effect of microtubule network
disruption on shear-free LFA-1-independent migration of mouse
T cells, similar to previous assays using primary human T cells
performed in the absence of LFA-1 ligands (44, 46). In support of
this, a recent publication found that murine T cells in cell cycle
accumulated and migrated efficiently within infected tissue (47),
indicating that cell cycling per se does not generate an overall lack
of motility.
Although PKC has been reported to mediate CCR7 phospho-
rylation and desensitization (27), we found that PKC inhibition
did not rescue the defective migration of recently activated CD4+
T cells. Owing to a lack of appropriate mAbs, we were unable to
examine CCR7 phosphorylation levels in the presence or absence
of PKC activity (not shown). We can therefore not exclude a
regulatory function of PKC function on chemokine receptors
in T cell. However, the fact that chemokinetic motility of acti-
vated T cells was also decreased supports a general migratory
defect in these cells. In this context, a recent publication demon-
strated that coupling of the plasma membrane to the underlying
actin cytoskeleton by the adaptor molecule myosin 1g (myo1g)
determines membrane tension (48). Since myo1g expression is
transiently augmented after TCR activation (http://www.immgen.
org), this may contribute to increased membrane tension and as
a consequence, a general reduction in cell motility. Future experi-
ments need to be performed to address themolecularmechanisms
underlying temporal unresponsiveness.
In sum,we have used a carefully calibrated in vivo inflammation
system in combination with flow cytometry and in vitro chemo-
taxis to investigate the migratory properties of TCR-stimulated
CD4+ T cells and its relation with chemokine receptors, integrins,
PKC activity, and the microtubular network. Although we were
unable to reverse the decreasedmigration through pharmacologi-
cal intervention, we hypothesize that the intrinsic low-cellmotility
may constitute a mechanism that contributes to sequestering of
activated CD4+ T cells in reactive PLNs, similar to increased
surface CD69 and decreased S1P1 mRNA expression (36).
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